WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)

被引：0
|
作者：
Berenson, J. [1 ]
Cartmell, A. [2 ]
Lyons, R. [3 ,4 ]
Harb, W. [5 ]
Tzachanis, D. [6 ]
Agajanian, R. [7 ]
Boccia, R. [8 ]
Coleman, M. [9 ]
Moss, R. A. [10 ]
Rifkin, R. M. [11 ,12 ]
Schupp, M. [13 ]
Dixon, S. [13 ]
Ou, Y. [13 ]
Anderl, J. [13 ]
Berdeja, J. [14 ]
机构：
[1] Inst Myeloma & Bone Canc Res, Los Angeles, CA USA
[2] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[3] US Oncol Res Ctr South Texas, San Antonio, TX USA
[4] US Canc Care Ctr South Texas, San Antonio, TX USA
[5] Horizon Oncol Ctr, Lafayette, IN USA
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Oncol Inst Hope & Innovat, Downey, CA USA
[8] Ctr Canc & Blood Disorders, Bethesda, MD USA
[9] NewYork Presbyterian Weill Cornell, New York, NY USA
[10] Robert A Moss MD Inc, Fountain Valley, CA USA
[11] US Oncol Res Canc Ctr, Denver, CO USA
[12] US Rocky Mt Canc Ctr, Denver, CO USA
[13] Amgen Inc, Thousand Oaks, CA USA
[14] Sarah Cannon Res Inst, Nashville, TN USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P661
引用
收藏
页码：261 / 262
页数：2
相关论文
共 50 条
  • [1] WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)
    Berenson, J.
    Cartmell, A.
    Lyons, R. M.
    Harb, W.
    Tzachanis, D.
    Boccia, R.
    Rifkin, R. M.
    Patel, P.
    Dixon, S.
    Berdeja, J.
    HAEMATOLOGICA, 2015, 100 : 81 - 81
  • [2] Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)
    Berenson, James
    Cartmell, Alan
    Lyons, Roger
    Harb, Wael
    Tzachanis, Dimitrios
    Agajanian, Richy
    Boccia, Ralph V.
    Coleman, Morton
    Moss, Robert A.
    Rifkin, Robert M.
    Schupp, Marco
    Dixon, Sandra
    Ou, Ying
    Anderl, Janet
    Berdeja, Jesus G.
    BLOOD, 2015, 126 (23)
  • [3] CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
    Berenson, James R.
    Cartmell, Alan
    Bessudo, Alberto
    Lyons, Roger M.
    Harb, Wael
    Tzachanis, Dimitrios
    Agajanian, Richy
    Boccia, Ralph
    Coleman, Morton
    Moss, Robert A.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Anderl, Janet
    Aggarwal, Sanjay
    Berdeja, Jesus G.
    BLOOD, 2016, 127 (26) : 3360 - 3368
  • [4] Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
    Berenson, James R.
    Cartmell, Alan
    Bessudo, Alberto
    Lyons, Roger M.
    Harb, Wael A.
    Tzachanis, Dimitrios
    Coleman, Morton
    Boccia, Ralph V.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Berdeja, Jesus G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
    Berenson, James R.
    Klein, Leonard
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Cartmell, Alan
    BLOOD, 2013, 122 (21)
  • [6] Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
    Berenson, James R.
    Klein, Leonard M.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Cartmell, Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Efficacy and Safety of Once-Weekly Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the CHAMPION-1 Study by Prior Lines of Therapy
    Berdeja, Jesus
    Rifkin, Robert
    Lyons, Roger
    Cartmell, Alan
    Coleman, Morton
    Yang, Hui
    Zahlten-Kumeli, Anita
    Iskander, Karim
    Berenson, James
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E58 - E59
  • [8] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    Blood Cancer Journal, 9
  • [9] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [10] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
12345